Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Interspond, LLC

Neither a doctor nor a teaching hospital

Research payments

$3,856,789

509 payments

Through program year 2025, Interspond, LLC is reported as receiving $3,856,789 in research payments, across 509 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $732,950 99
2024 Research $1,175,518 50
2023 Research $220,986 31
2022 Research $537,792 103
2021 Research $423,974 43
2020 Research $392,472 62
2019 Research $373,096 121

Breakdown

Who paid Research payments · program years 2019–2025
  1. Axsome Therapeutics, Inc. $1,064,502 38 payments
  2. Gilead Sciences, Inc. $670,511 166 payments
  3. CSL Behring $468,934 35 payments
  4. Organon LLC $420,596 28 payments
  5. E.R. Squibb & Sons, L.L.C. $373,750 13 payments
  6. Incyte Corporation $286,243 79 payments
  7. Applied Therapeutics, inc. $189,834 49 payments
  8. Genentech, Inc. $120,079 13 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $76,132 40 payments
  10. Novartis Pharmaceuticals Corporation $44,906 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms $1,064,502 38 payments
  2. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in Adults With Dermatomyositis (DM) $335,540 28 payments
  3. Og-8175A-023 $238,495 14 payments
  4. The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. $214,433 69 payments
  5. Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $189,834 49 payments
  6. Og-8175A-023 $182,100 14 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease $157,728 2 payments
  8. Ensemble $120,079 13 payments
  9. A Randomized, Multicenter, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of IgPro10 (Intravenous Immunoglobulin, Privigen) for the Treatment of Adults With Systemic Sclerosis $116,480 1 payment
  10. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $82,090 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $420,596 28 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record